BGM0504 Administered is named as an intervention in 2 current clinical trials in our China register. 2 are recruiting patients now. All registered phases are Phase 3. The sponsor with the most trials is BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd (1). The most-studied condition is Overweight or Obesity.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study of BGM0504 Injection in Participants with Obesity or Overweight
NCT06704581 · ClinicalTrials.gov ↗ · Overweight or Obesity
|
Phase 3 | Recruiting | BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd. | China |
|
A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise
NCT06716203 · ClinicalTrials.gov ↗ · Type 2 Diabetes Mellitus (T2DM)
|
Phase 3 | Recruiting | BrightGene Bio-Medical Technology Co., Ltd. | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd. | 1 |
| BrightGene Bio-Medical Technology Co., Ltd. | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 2 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China register name BGM0504 Administered as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 2 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd (1) and BrightGene Bio-Medical Technology Co., Ltd (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how BGM0504 Administered works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how BGM0504 Administered works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists BGM0504 Administered (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.